Preparation and application of a glycated hemoglobin control product

By preparing the glycated hemoglobin concentrate and adding mannitol and polyethylene glycol 6000, lyophilized hemoglobin quality control products, the problems of poor stability of quality control products and expensive instruments in the existing technology are solved, and long-term stability and wide application are achieved quality control product preparation.

CN114755085BActive Publication Date: 2024-11-12DAAN GENE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210467323.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-29
Publication Date
2024-11-12
Estimated Expiration
2042-04-29

AI Technical Summary

Technical Problem

The existing glycated hemoglobin control products have short shelf life and poor stability, which cannot meet the clinical use needs. The existing preparation methods require expensive instruments and residual reducing agents affect the determination results.

Method used

By obtaining whole hemoglobin cells of healthy humans, prepare saccharified hemoglobin concentrate, mix and dilute, add mannitol and polyethylene glycol 6000, and freeze-dried to prepare high-value and low-value saccharified hemoglobin quality control lyophilized powder to achieve good stability Control preparation.

Benefits of technology

The prepared glycated hemoglobin control product has good stability, and the glycated hemoglobin value is within the mean ±10% range within 24 months of storage. It is suitable for peroxidase method and latex enhanced immune turbidity method, and is more widely used.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114755085B_ABST
    Figure CN114755085B_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a glycated hemoglobin control product and its application. The glycated hemoglobin control product preparation method of the invention is simple, and the glycated hemoglobin control product can be quickly prepared without complicated operations and expensive instruments; the prepared glycated hemoglobin control product has good stability, and the glycated hemoglobin value is within the range of ±10% of the mean value within 2-8°C storage for 24 months, and the storage time is long.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medical testing and determination, and specifically relates to the preparation and application of a glycosylated hemoglobin control product. Background Art

[0002] Glycated hemoglobin (HbA1c) is the product of hemoglobin in red blood cells and sugars (mainly glucose) in serum through non-enzymatic reactions. It is generally believed that the concentration of glycated hemoglobin can effectively reflect the average blood sugar level in the past 8 to 12 weeks. Glycated hemoglobin is composed of HbA1a, HbA1b, and HbA1c, of which HbA1c accounts for about 70% and has a relatively stable structure. It is often used as a monitoring indicator for diabetes control in clinical practice.

[0003] At present, there are many methods for clinically measuring the content of glycated hemoglobin (HbA1c), such as ion exchange chromatography (HPLC), affinity chromatography, electrophoresis, immunoassay, enzyme method, etc. Before clinical measurement, each measurement method needs to be calibrated with a calibrator, and the measurement system needs to be quality controlled with a quality control product. Existing whole blood calibrators and quality control products have the problems of short shelf life and poor stability, which is not conducive to the clinical use of whole blood calibrators and quality control products. Generally speaking, the glycated hemoglobin concentration of normal people is less than 6.5%, and the acquisition of different concentration values ​​is random and uncontrollable, which is not conducive to production.

[0004] The prior art discloses a method for preparing different concentrations of glycosylated hemoglobin control products: extracting red blood cells from normal human whole blood and further preparing high-concentration glycosylated hemoglobin using ion affinity chromatography, but the instruments involved in ion affinity chromatography are expensive and the sample processing speed is slow, which is not conducive to actual scale-up production and cannot meet practical applications. Although the prior art provides a method for preparing glycosylated hemoglobin control products by rapidly processing hemoglobin through glycosylation, the reaction liquid component contains a reducing agent when the hemoglobin undergoes a glycosylation reaction, and there is no step of removing the reducing agent in the subsequent purification process, that is, the final product (glycosylated hemoglobin control product) has a large amount of reducing agent remaining; the product has no effect as a latex enhanced immunoturbidimetric glycosylated hemoglobin assay kit; however, when used as a peroxidase glycosylated hemoglobin assay kit quality control product, it cannot be tested due to the large amount of residual reducing agent. Peroxidase method and latex enhanced immunoturbidimetry are both commonly used methods for using glycated hemoglobin determination kits. Therefore, it is very necessary to provide a new preparation method that is simpler and faster to prepare glycated hemoglobin control products of different concentrations suitable for peroxidase method and latex enhanced immunoturbidimetry. Summary of the invention

[0005] The technical problem to be solved by the present invention is to overcome the defects and shortcomings of the existing preparation of glycated hemoglobin control products and provide a preparation method and application of a glycated hemoglobin control product.

[0006] The object of the present invention is to provide a method for preparing a glycated hemoglobin control product.

[0007] The present invention also aims to provide a glycated hemoglobin control product prepared by the preparation method.

[0008] The present invention also aims to provide the use of the glycated hemoglobin control product in the quality control of glycated hemoglobin.

[0009] The above-mentioned purpose of the present invention is achieved by the following technical means:

[0010] The present invention first prepares two concentrations of glycated hemoglobin concentrates, then dilutes the two concentrations of glycated hemoglobin concentrates and mixes them in a specific ratio to prepare a high-value glycated hemoglobin control solution and a low-value glycated hemoglobin control solution; finally, a high-value glycated hemoglobin control freeze-dried powder and a low-value glycated hemoglobin control freeze-dried powder are prepared by adding a specific ratio of mannitol and polyethylene glycol 6000. The freeze-dried powder prepared by the present invention has good stability, and the glycated hemoglobin value is within the range of ±10% of the mean value within 2-8°C for 24 months, and the storage time is long.

[0011] A method for preparing a glycated hemoglobin control product comprises the following steps:

[0012] S1. Obtain whole blood red blood cells from a healthy person, dissolve the red blood cells, obtain a hemoglobin solution, filter, and obtain a glycated hemoglobin solution 1; and fully concentrate by ultrafiltration to obtain a concentrated solution of the glycated hemoglobin solution 1;

[0013] S2. The glycated hemoglobin solution 1 prepared in step S1 is mixed with glucose, the final concentration of glucose in the mixed solution is 16 to 36 mmol / L, and the mixed solution is incubated at 36 to 38° C. for 30 to 60 days; then, unreacted glucose is removed, and ultrafiltration is performed to fully concentrate to obtain a concentrated solution of the glycated hemoglobin solution 2;

[0014] S3. The concentrated solution of glycated hemoglobin solution 1 prepared in step S1 and the concentrated solution of glycated hemoglobin solution 2 prepared in step S2 are diluted to a hemoglobin concentration of 110 to 130 g / L, respectively, to obtain a diluent of the concentrated solution of glycated hemoglobin solution 1 and a diluent of the concentrated solution of glycated hemoglobin solution 2; the diluent of the concentrated solution of glycated hemoglobin solution 1 is mixed with the diluent of the concentrated solution of glycated hemoglobin solution 2 at a volume ratio of 1:1 to 1:5 to obtain a high-value glycated hemoglobin solution; the diluent of the concentrated solution of glycated hemoglobin solution 1 is mixed with the diluent of the concentrated solution of glycated hemoglobin solution 2 at a volume ratio of 10:1 to 15:1 to obtain a low-value glycated hemoglobin solution;

[0015] S4. The high-value glycated hemoglobin solution prepared in step S3 is mixed with mannitol and polyethylene glycol 6000, and the mixture is freeze-dried to obtain a high-value glycated hemoglobin control product; the low-value glycated hemoglobin solution prepared in step S3 is mixed with mannitol and polyethylene glycol 6000, and the mixture is freeze-dried to obtain a low-value glycated hemoglobin control product; the final concentration of mannitol in the mixed solution is 70-100 g / L, and the final concentration of polyethylene glycol 6000 is 5-20 g / L.

[0016] The healthy person refers to a person whose blood sample does not contain viruses such as HIV, hepatitis B, and hepatitis C.

[0017] Preferably, the filtration in step S1 is performed using a 0.2-0.3 μM filter.

[0018] Further preferably, the filtration in step S1 is performed using a 0.22 μM filter.

[0019] Preferably, the ultrafiltration and concentration in step S1 is performed using a 25-35KD ultrafiltration centrifuge tube.

[0020] Further preferably, the ultrafiltration concentration in step S1 is performed using a 30KD ultrafiltration centrifuge tube.

[0021] Preferably, in step S1, the volume ratio of the concentrated glycosylated hemoglobin solution 1 to the hemoglobin solution is 1:3-5.

[0022] Further preferably, in step S1, the volume ratio of the concentrated glycated hemoglobin solution 1 to the hemoglobin solution is 1:4.

[0023] Preferably, in step S2, the volume ratio of the concentrated glycated hemoglobin solution 2 to the glycated hemoglobin solution 1 is 1:3-5.

[0024] Further preferably, in step S2, the volume ratio of the concentrated glycated hemoglobin solution 2 to the glycated hemoglobin solution 1 is 1:4.

[0025] Preferably, in step S2, the final concentration of glucose in the mixed solution is 36 mmol / L, and the mixed solution is incubated at 37° C. for 30 days.

[0026] Preferably, in step S2, the final concentration of glucose in the mixed solution is 18 mmol / L, and the mixed solution is incubated at 37° C. for 60 days.

[0027] Preferably, in step S2, glucose oxidase is used to remove unreacted glucose and hydrogen peroxide.

[0028] More preferably, the glucose oxidase is used at a concentration of 8 to 12 KU / L.

[0029] More preferably, the glucose oxidase is used at a concentration of 10 KU / L.

[0030] Preferably, the ultrafiltration and concentration in step S2 is performed using a 25-35KD ultrafiltration centrifuge tube.

[0031] Further preferably, the ultrafiltration concentration in step S2 is performed using a 30KD ultrafiltration centrifuge tube.

[0032] Preferably, in step S3, the concentrated solution of glycated hemoglobin solution 1 prepared in step S1 and the concentrated solution of glycated hemoglobin solution 2 prepared in step S2 are diluted to a hemoglobin concentration of 120 g / L, respectively.

[0033] Preferably, in step S3, the dilution of the concentrated solution of glycated hemoglobin solution 1 is mixed with the dilution of the concentrated solution of glycated hemoglobin solution 2 at a volume ratio of 1:1 to obtain a high-value glycated hemoglobin solution; the dilution of the concentrated solution of glycated hemoglobin solution 1 is mixed with the dilution of the concentrated solution of glycated hemoglobin solution 2 at a volume ratio of 10:1 to obtain a low-value glycated hemoglobin solution.

[0034] Preferably, in step S4, the final concentration of mannitol in the mixed solution is 70-80 g / L, and the final concentration of polyethylene glycol 6000 is 5-10 g / L.

[0035] Further preferably, in step S4, the final concentration of mannitol in the mixed solution is 70 g / L, and the final concentration of polyethylene glycol 6000 is 5 g / L.

[0036] The glycated hemoglobin control product prepared by the preparation method is also within the protection scope of the present invention.

[0037] The application of the glycated hemoglobin protein control product in the quality control of glycated hemoglobin is also within the protection scope of the present invention.

[0038] Compared with the prior art, the present invention has the following beneficial effects:

[0039] The method for preparing the glycated hemoglobin control product of the present invention is simple, and the glycated hemoglobin control product can be quickly prepared without complicated operations and expensive instruments; the prepared glycated hemoglobin control product has good stability, and the glycated hemoglobin value is within the range of ±10% of the mean value within 24 months of storage at 2-8°C, and the storage time is long; and the product can be simultaneously used in glycated hemoglobin determination kits of the peroxidase method and the latex enhanced immunoturbidimetry method, and has a wider application. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 This is a stability monitoring chart of the quality control product 1 glycated hemoglobin control product freeze-dried powder of the present invention, wherein A is a low value and B is a high value.

[0041] Figure 2 This is a stability monitoring chart of the quality control product 2, glycated hemoglobin control product freeze-dried powder of the present invention, wherein A is a low value and B is a high value.

[0042] Figure 3 This is a stability monitoring chart of the quality control product 3 glycated hemoglobin control product freeze-dried powder of the present invention, wherein A is a low value and B is a high value.

[0043] Figure 4 This is a stability monitoring chart of the lyophilized powder of the glycated hemoglobin control product 1 of the present invention, wherein A is a low value and B is a high value.

[0044] Figure 5 This is a stability monitoring chart of the lyophilized powder of the glycated hemoglobin control product 2 of the present invention, wherein A is a low value and B is a high value. DETAILED DESCRIPTION

[0045] The present invention is further described below with reference to specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0046] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0047] Example 1 Preparation of Glycated Hemoglobin Solution 1 Concentrate

[0048] 1. Red Blood Cell Processing

[0049] 200 mL of EDTA anticoagulated whole blood samples were collected from healthy people. Each sample was tested for HIV (HIV1, HIV2) antibodies, hepatitis B surface antigen (HbsAg) and hepatitis C virus (HCV) antibodies. Those with negative results were collected for use. If one of them was positive, the sample was handled in accordance with the relevant medical waste disposal regulations. The collected whole blood samples were centrifuged at about 1900 g, the upper plasma was discarded, and physiological saline was added. The red blood cells were repeatedly blown and washed with a pipette, and then centrifuged after washing. The upper physiological saline was discarded, and the washing was repeated 3 times to prepare washed red blood cells.

[0050] 2. Preparation of Glycated Hemoglobin Solution 1 Concentrate

[0051] (1) Treatment solution preparation

[0052] Take 0.2 g of 3-sulfopropyltetradecyl dimethyl betaine and 0.028 g of sodium nitrite and fully dissolve them in 100 mL of pure water.

[0053] (2) Preparation of Glycated Hemoglobin Solution 1 Concentrate

[0054] The washed red blood cells and the treatment solution are fully mixed in a volume ratio of 1:1 to dissolve the red blood cells to obtain a hemoglobin solution, and the obtained hemoglobin solution (100 mL) is filtered through a 0.22 μM filter to obtain a glycated hemoglobin solution 1; the glycated hemoglobin solution 1 is concentrated using an ultrafiltration centrifuge tube with a retention rate of 30KD and a centrifugal force of 14000g, and centrifuged for 10 minutes to obtain a concentrated solution of glycated hemoglobin solution 1 (25 mL), which is stored at 2-8°C for future use.

[0055] Example 2 Preparation of Glycated Hemoglobin Solution 2 Concentrate

[0056] Take the glycated hemoglobin solution 1 (100 mL) prepared in Example 1, add glucose and dissolve it, the final concentration of glucose is 18 mmol / L, and then place the mixed solution at 37 ° C for incubation for 60 days. After the incubation, add glucose oxidase to remove unreacted glucose and terminate the glycosylation reaction. The final concentration of glucose oxidase is 10 KU / L. The solution after removing glucose is placed at 37 ° C for 7 days to eliminate hydrogen peroxide; finally, use an ultrafiltration centrifuge tube with a retention rate of 30KD for concentration treatment, 14000g centrifugal force, centrifuge for 10 minutes to obtain a concentrated solution of glycated hemoglobin solution 2 (25 mL); 2-8 ° C storage for standby.

[0057] Example 3 Preparation of Glycated Hemoglobin Solution 2 Concentrate

[0058] Take the glycated hemoglobin solution 1 (100 mL) prepared in Example 1, add glucose and dissolve it, the final concentration of glucose is 36 mmol / L, and then place the mixed solution at 37°C for incubation for 30 days. After the incubation, add glucose oxidase to remove unreacted glucose and terminate the glycosylation reaction. The final concentration of glucose oxidase is 10 KU / L. The solution after removing glucose is placed at 37°C for 7 days to eliminate hydrogen peroxide; finally, use an ultrafiltration centrifuge tube with a retention rate of 30 KD for concentration treatment, 14000g centrifugal force, centrifuge for 10 minutes to obtain a concentrated solution of glycated hemoglobin solution 2 (25 mL); store at 2-8°C for standby use.

[0059] Example 4 Preparation of Glycated Hemoglobin Control Solution

[0060] The concentrated solution of glycated hemoglobin solution 1 prepared in Example 1 and the concentrated solution of glycated hemoglobin solution 2 prepared in Example 2 were diluted with pure water to prepare a dilution of the concentrated solution of glycated hemoglobin solution 1 (mother solution B) and a dilution of the concentrated solution of glycated hemoglobin solution 2 (mother solution A) both of which had a hemoglobin concentration of 120 g / L. The values ​​were determined using a fully automatic blood analyzer, and the mother solutions A and B were determined using a glycated hemoglobin kit (Sekisui Medical Technology (China) Co., Ltd., 838RHQ), respectively. The glycated hemoglobin value of the mother solution A was 15.9%, and the glycated hemoglobin value of the mother solution B was 4.5%.

[0061] The mother solution A and the mother solution B are mixed, and the mother solution B and the mother solution A are mixed at a volume ratio of 10:1 to obtain a low-value quality control solution 1. After measurement, the glycated hemoglobin value of the low-value quality control solution is 5.5%;

[0062] The mother solution B and the mother solution A were mixed at a volume ratio of 1:1 to obtain a high-value quality control solution. After measurement, the glycated hemoglobin value of the high-value quality control solution 1 was 11.7%.

[0063] The mother solution A and the mother solution B are mixed, and the mother solution B and the mother solution A are mixed at a volume ratio of 15:1 to obtain a low-value quality control solution 2. After measurement, the glycated hemoglobin value of the low-value quality control solution is 5.1%;

[0064] The mother solution B and the mother solution A were mixed at a volume ratio of 1:5 to obtain a high-value quality control solution. After measurement, the glycated hemoglobin value of the high-value quality control solution 2 was 16.8%.

[0065] Example 5 Preparation of Glycated Hemoglobin Control Lyophilized Powder

[0066] 1. Methods

[0067] (1) Preparation of freeze-dried powder

[0068] The excipient mannitol and the stabilizer polyethylene glycol 6000 were added to the high-value quality control solution 1 and the low-value quality control solution 1 prepared in Example 4 respectively and fully dissolved, and the mixed solution was packaged into 0.5 mL bottles per bottle, -55°C to -50°C, the vacuum degree is less than 3 Pa, freeze-dried for 24 hours, and then sealed for use.

[0069] The lyophilized powder prepared with a final concentration of mannitol of 70 g / L and a final concentration of polyethylene glycol 6000 of 5 g / L in the mixed solution was used as quality control product 1;

[0070] The lyophilized powder prepared with a final concentration of mannitol of 80 g / L and a final concentration of polyethylene glycol 6000 of 10 g / L in the mixed solution was used as quality control product 2;

[0071] The lyophilized powder prepared with a final concentration of mannitol of 100 g / L and a final concentration of polyethylene glycol 6000 of 20 g / L in the mixed solution was used as quality control product 3;

[0072] The lyophilized powder prepared with a final concentration of mannitol of 40 g / L and a final concentration of polyethylene glycol 6000 of 2 g / L in the mixed solution was used as comparative quality control product 1;

[0073] The lyophilized powder prepared with the final concentration of mannitol at 70 g / L and the final concentration of polyethylene glycol 6000 at 30 g / L in the mixed solution was used as comparative quality control product 2.

[0074] (2) Quality control setting

[0075] Take 10 bottles of freeze-dried powder respectively, add 0.5 mL of pure water to dissolve them respectively, test the quality control of each bottle with the glycated hemoglobin kit and determine the target value. The target value is the average of the 10 bottles, and the quality control range is ±10% of the target value.

[0076] (3) Determination of freeze-dried powder stability

[0077] The high and low value glycosylated hemoglobin protein control freeze-dried powder is stored at 2-8°C. One bottle is randomly selected every month and tested with a glycosylated hemoglobin assay kit to monitor its stability.

[0078] 2. Results

[0079] The fixed values ​​and ranges of the lyophilized powders of each glycated hemoglobin control product are shown in Table 1; the stability of each lyophilized powder of the glycated hemoglobin control product is shown in Table 2; the stability monitoring chart of the lyophilized powder of the glycated hemoglobin control product 1 is shown in Figure 1 , where A is the low value and B is the high value; the stability monitoring chart of the quality control product 2 glycosylated hemoglobin control product freeze-dried powder is as follows Figure 2 , where A is the low value and B is the high value; the stability monitoring chart of the quality control product 3 glycosylated hemoglobin control product freeze-dried powder is as follows Figure 3 , where A is the low value and B is the high value; the stability monitoring chart of the control product 1 glycated hemoglobin control freeze-dried powder is shown in Figure 4, where A is the low value and B is the high value; the stability monitoring chart of the control product 2, glycosylated hemoglobin control product freeze-dried powder, is shown in Figure 5 , where A is a low value and B is a high value.

[0080] Table 1 The fixed values ​​and ranges of lyophilized powder of glycated hemoglobin control products

[0081]

[0082]

[0083] Table 1 shows that in the finished product of freeze-dried glycated hemoglobin, the average low value of quality control product 1 is 5.6, and the average high value is 11.5; the average low value of quality control product 2 is 6.3, and the average high value is 12.2; the average low value of quality control product 3 is 6.2, and the average high value is 12; the average low value of comparison quality control product 1 is 6.6, and the average high value is 12.7; the average low value of comparison quality control product 2 is 6.3, and the average high value is 12.2.

[0084] Table 2 Stability of lyophilized powder of glycated hemoglobin control products

[0085]

[0086]

[0087] From the data in Table 2 and Figures 1 to 5 It can be seen that the fixed values ​​of quality control products 1, quality control products 2 and quality control products 3 after 24 months of storage are maintained at ±10% of the target value, indicating that quality control products 1, quality control products 2 and quality control products 3 are still stable after 24 months of storage; while the fixed values ​​of comparative quality control products 1 and 2 after 14 months of storage are beyond ±10% of the target value, indicating that comparative quality control products 1 and 2 cannot be stably stored within 24 months, and the stability of quality control products 1, quality control products 2 and quality control products 3 is better than that of comparative quality control products 1 and 2. Compared with quality control products 1, 2 and 3, comparative quality control products 1 and 2 only change in the concentration of mannitol and polyethylene glycol 6000, indicating that the concentration of mannitol and polyethylene glycol 6000 has a significant effect on the stability of lyophilized powder of glycated hemoglobin control products.

[0088] In summary, only by adding mannitol and polyethylene glycol 6000 in the concentration range of the present invention can the stable glycosylated hemoglobin control freeze-dried powder of the present invention be prepared. The final concentration range of mannitol in the mixed solution is 70-100 g / L; the final concentration range of polyethylene glycol 6000 is 5-20 g / L.

[0089] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A method for preparing a glycated hemoglobin control product, characterized in that: The following steps are involved: S1. Obtain whole red blood cells from a healthy person, dissolve the red blood cells, obtain a hemoglobin solution, filter it, and obtain a glycosylated hemoglobin solution 1; Ultrafiltration is performed to fully concentrate to obtain a concentrated solution of glycated hemoglobin solution 1; S2. The glycated hemoglobin solution 1 prepared in step S1 is mixed with glucose, the final concentration of glucose in the mixed solution is 16 to 36 mmol / L, and the mixed solution is incubated at 36 to 38° C. for 30 to 60 days; then, unreacted glucose is removed, and ultrafiltration is performed to fully concentrate to obtain a concentrated solution of the glycated hemoglobin solution 2; S3. diluting the concentrated solution of glycated hemoglobin solution 1 prepared in step S1 and the concentrated solution of glycated hemoglobin solution 2 prepared in step S2 to a hemoglobin concentration of 110 to 130 g / L, respectively, to obtain a diluted solution of the concentrated solution of glycated hemoglobin solution 1 and a diluted solution of the concentrated solution of glycated hemoglobin solution 2; The dilution of the concentrated solution of glycated hemoglobin solution 1 is mixed with the dilution of the concentrated solution of glycated hemoglobin solution 2 at a volume ratio of 1:1 to 1:5 to obtain a high-value glycated hemoglobin solution; the dilution of the concentrated solution of glycated hemoglobin solution 1 is mixed with the dilution of the concentrated solution of glycated hemoglobin solution 2 at a volume ratio of 10:1 to 15:1 to obtain a low-value glycated hemoglobin solution; S4. The high-value glycated hemoglobin solution prepared in step S3 is mixed with mannitol and polyethylene glycol 6000, and the mixture is freeze-dried to obtain a high-value glycated hemoglobin control product; the low-value glycated hemoglobin solution prepared in step S3 is mixed with mannitol and polyethylene glycol 6000, and the mixture is freeze-dried to obtain a low-value glycated hemoglobin control product; the final concentration of mannitol in the mixed solution is 70-100 g / L, and the final concentration of polyethylene glycol 6000 is 5-20 g / L.

2. The preparation method according to claim 1, characterized in that: In step S1, the volume ratio of the concentrated glycated hemoglobin solution 1 to the hemoglobin solution is 1:3-5; in step S2, the volume ratio of the concentrated glycated hemoglobin solution 2 to the glycated hemoglobin solution 1 is 1:3-5.

3. The preparation method according to claim 1, characterized in that: In step S2, unreacted glucose is removed by glucose oxidase, and hydrogen peroxide is removed.

4. The preparation method according to claim 3, characterized in that: The glucose oxidase is used at a concentration of 8 to 12 KU / L.

5. The preparation method according to claim 1, characterized in that: In step S2, the final concentration of glucose in the mixed solution is 18 mmol / L, and the mixed solution is incubated at 37°C for 60 days.

6. The preparation method according to claim 1, characterized in that: In step S3, the concentrated solution of glycated hemoglobin solution 1 prepared in step S1 and the concentrated solution of glycated hemoglobin solution 2 prepared in step S2 are diluted to a hemoglobin concentration of 120 g / L.

7. The preparation method according to claim 1, characterized in that: In step S3, the dilution of the concentrated solution of glycated hemoglobin solution 1 and the dilution of the concentrated solution of glycated hemoglobin solution 2 are mixed at a volume ratio of 1:1 to obtain a high-value glycated hemoglobin solution; the dilution of the concentrated solution of glycated hemoglobin solution 1 and the dilution of the concentrated solution of glycated hemoglobin solution 2 are mixed at a volume ratio of 10:1 to obtain a low-value glycated hemoglobin solution.

8. The preparation method according to claim 1, characterized in that: In step S4, the final concentration of mannitol in the mixed solution is 70-80 g / L, and the final concentration of polyethylene glycol 6000 is 5-10 g / L.

9. A glycated hemoglobin control product prepared by the preparation method according to any one of claims 1 to 8.

10. Use of the glycated hemoglobin control product according to claim 9 in the quality control of glycated hemoglobin.